Lyndra Therapeutics

Healthcare & Life Sciences

Recent Finacing

Series E

Recent Raise

$101M

Lyndra Therapeutics is a clinical-stage biopharmaceutical company developing long-acting oral drug therapies, including a once-weekly oral version of risperidone for psychiatric disorders.

Total Funding

$101M

Headquarters

Watertown, USA

Founded

N/A

Website

lyndra.com

Focus Areas

Clinical-stage biopharmaceutical

Long-acting oral therapies

Series E funding

Oral weekly risperidone

Phase 3 study

Global market licensing

Investors